Forest Services
Overreliance on FDA in Global Health Governance
The U.S. Food and Drug Administration (FDA) serves as a dominant regulatory authority in global health, approving approximately 50% of new molecular entities annually (FDA Annual Report 2023). Operating under the Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938, the FDA’s decisions heavily influence global pharmaceutical markets, given the U.S.'s 20% share of the USD 1.5 trillion global pharmaceutical market (Statista 2024). However, this centrality creates bottlenecks for other nations, particularly low- and middle-income countries (LMICs), which face delays averaging 12-18 months due to dependence on FDA certifications (Pharma Export Promotion Council 2023). The World Health Organization (WHO), mandated by its 1948 Constitution and the International Health Regulations (IHR) 2005, lacks enforcement mechanisms to counterbalance FDA dominance in pandemic preparedness and regulatory harmonization.
UPSC Relevance
- GS Paper 2: Governance - International institutions, health governance frameworks
- GS Paper 3: Economic Development - Pharmaceutical sector, global trade, pandemic preparedness
- Essay: Global governance and health equity
Legal and Institutional Frameworks Governing Drug Regulation
India’s domestic drug regulation is governed by the Drugs and Cosmetics Act, 1940 (Sections 3, 18, and 27), which regulates manufacture, sale, and import of drugs. Internationally, the WHO’s Constitution (1948) provides the legal basis for global health coordination, while the International Health Regulations (IHR) 2005 bind 196 countries to disease surveillance and response, albeit without binding enforcement (WHO IHR Annual Report 2023). The FDA’s authority is national but extends global influence due to market size and regulatory stringency. Other key institutions include the European Medicines Agency (EMA), which regulates medicines across 27 EU states, and India’s Central Drugs Standard Control Organization (CDSCO), the national regulator. The International Council for Harmonisation (ICH) attempts to harmonize technical requirements but has limited enforcement power.
Economic Consequences of FDA-Centric Regulation
The global pharmaceutical market’s valuation at USD 1.5 trillion contrasts with WHO’s modest pandemic preparedness budget of around USD 1 billion annually, underscoring resource asymmetry (Statista 2024; WHO Budget 2023). India’s pharmaceutical exports, valued at USD 24.44 billion in FY 2022-23, are hampered by regulatory delays linked to FDA dependence (Pharma Export Promotion Council 2023). These delays restrict timely access to medicines in LMICs, exacerbating health inequities. FDA Emergency Use Authorizations (EUAs) during COVID-19 accelerated approvals for 20 vaccines and therapeutics, but WHO prequalification lagged by six months on average, delaying global distribution (Lancet Global Health 2023). The FDA’s multi-billion-dollar budget dwarfs WHO’s regulatory funding, limiting WHO’s capacity to provide a truly global regulatory alternative.
Comparative Analysis: FDA vs EMA Regulatory Models
| Aspect | FDA (USA) | EMA (European Union) |
|---|---|---|
| Jurisdiction | National (USA) | Supranational (27 EU states) |
| Approval Time (Pandemic) | ~300 days | ~210 days (30% faster) |
| Regulatory Approach | Centralized | Decentralized, collaborative |
| Market Share Influence | 20% global pharmaceutical market | ~15% global pharmaceutical market |
| Impact on Access | Regulatory bottlenecks delay LMIC access | Broader access across diverse populations |
The EMA’s decentralized, collaborative framework across multiple member states contrasts with the FDA’s centralized model. EMA’s faster approval times during the pandemic demonstrate the benefits of multipolar governance in improving access and regulatory efficiency (EMA 2023 Report). This model also dilutes single-country dominance, fostering regulatory diversity and resilience.
Critical Gaps in Global Health Governance
- FDA’s dominance creates regulatory bottlenecks that delay access to medicines in LMICs, undermining equitable health outcomes.
- WHO’s limited enforcement capacity under the IHR 2005 weakens global pandemic preparedness and coordination.
- Economic asymmetry between FDA’s regulatory budget and WHO’s funding limits the latter’s ability to provide an alternative global regulatory framework.
- India’s pharmaceutical sector faces export delays due to reliance on FDA approvals, impacting its role as the “pharmacy of the world.”
- Regulatory harmonization efforts via ICH lack binding authority, perpetuating fragmentation.
Way Forward: Towards Multipolar and Inclusive Global Health Governance
- Strengthen WHO’s regulatory authority and funding to enable faster prequalification and enforcement of international standards.
- Promote regional regulatory bodies (e.g., African Medicines Agency) to decentralize approval processes and reduce dependence on FDA.
- Enhance harmonization mechanisms under ICH with binding commitments to reduce duplication and delays.
- Encourage India’s CDSCO to align more closely with global standards and develop capacity to reduce export delays.
- Foster collaborative frameworks modeled on EMA’s decentralized approach to improve pandemic responsiveness and equitable access.
PRACTICE QUESTIONS
- The FDA has jurisdiction over drug approvals in all WHO member countries.
- The International Health Regulations (IHR) 2005 are legally binding but lack enforcement mechanisms.
- The European Medicines Agency (EMA) employs a decentralized regulatory approach across multiple countries.
Which of the above statements is/are correct?
- FDA approvals account for approximately half of new molecular entities globally each year.
- India’s pharmaceutical exports face delays averaging 12-18 months due to dependence on FDA certifications.
- WHO’s pandemic preparedness budget exceeds FDA’s regulatory budget.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 (Governance and International Relations)
- Jharkhand Angle: Jharkhand’s pharmaceutical manufacturing units depend on timely regulatory approvals for exports; delays due to FDA dependence impact local industry growth.
- Mains Pointer: Frame answers highlighting regulatory bottlenecks’ impact on state-level pharmaceutical sectors and the need for strengthening CDSCO and regional regulatory cooperation.
What is the legal basis for WHO’s role in global health governance?
The WHO’s role is established by its Constitution adopted in 1948, and further operationalized through the International Health Regulations (IHR) 2005, which bind 196 countries to coordinate disease surveillance and response.
Why does FDA dominance delay medicine access in low- and middle-income countries?
FDA’s centralized and stringent approval processes create bottlenecks; many LMICs rely on FDA certifications for market access, causing delays averaging 12-18 months, especially for Indian generic drug exports.
How does the EMA’s regulatory approach differ from the FDA’s?
EMA employs a decentralized, collaborative regulatory framework across 27 EU member states, enabling faster approvals (average 210 days) and broader access, unlike FDA’s centralized, US-only jurisdiction.
What are the limitations of the International Health Regulations (IHR) 2005?
IHR 2005 lack binding enforcement mechanisms, limiting WHO’s authority to compel member states to comply fully with pandemic preparedness and reporting obligations.
How can India reduce its dependence on FDA for pharmaceutical exports?
By strengthening the capacity and global alignment of the Central Drugs Standard Control Organization (CDSCO), enhancing regional regulatory cooperation, and participating actively in harmonization initiatives like ICH.